EMMA method, developed by a team from the Institute Curie in Paris, would better detect genetic mutations that are responsible for 5% of breast cancers and the ovary. Women with variations of either BRCA1 or BRCA2 have indeed a higher risk of developing a tumor
An 8-fold higher risk than the general population. The risk of ovarian cancer, it is for its part "very high" among these women, according to the Institut Curie. The new method EMMA (for Enhanced Mismatch Mutation Analysis ®) "to detect genetic alterations of large and small. Yet paradoxically, these are harder to spot, "explained Professor Dominique Stoppa-Lyonnet, head of cancer genetics at the Institut Curie.
Used on 1525 patients with either breast cancer or a tumor of the ovary, the new method has helped "detect genetic variation that had escaped the strategy we used previously," adds Dr Stoppa -Lyonnet. In addition to its greater efficiency, this method also allows for faster results. A complete genetic analysis takes four times less time than the technique used so far. In 2010, the Institut Curie EMMA technique was used for 700 searches pathogenic mutations in women meeting criteria specific risk. "These include the number of cancers in the family, their location, age of onset, type of cancer ... "We" she said.
In 2010, approximately 52,000 new cases of breast cancer were diagnosed in France. The number of new cases of ovarian cancer is estimated at 4500. Among them, the hereditary forms represent about 5% of breast cancers and 6% of ovarian cancers
http://www.destinationsante.com/Cancers-du-sein-et-de-l- ovarian-better-detected-the-predispositions.html
0 comments:
Post a Comment